• Heart Failure
  • Cardiovascular Clinical Consult
  • Adult Immunization
  • Hepatic Disease
  • Rare Disorders
  • Pediatric Immunization
  • Implementing The Topcon Ocular Telehealth Platform
  • Weight Management
  • Monkeypox
  • Guidelines
  • Men's Health
  • Psychiatry
  • Allergy
  • Nutrition
  • Women's Health
  • Cardiology
  • Substance Use
  • Pediatrics
  • Kidney Disease
  • Genetics
  • Complimentary & Alternative Medicine
  • Dermatology
  • Endocrinology
  • Oral Medicine
  • Otorhinolaryngologic Diseases
  • Pain
  • Gastrointestinal Disorders
  • Geriatrics
  • Infection
  • Musculoskeletal Disorders
  • Obesity
  • Rheumatology
  • Technology
  • Cancer
  • Nephrology
  • Anemia
  • Neurology
  • Pulmonology

Friday's 5 Quotes for Primary Care


SGLT-2 inhibitors show broad cardiometabolic efficacy; colchicine approved for CV inflammation, astronomical diabetes rates; plus 2 more quotes of note.

Each of the quotes that follow is taken from a study reviewed on Patient Care® during the past week and was chosen for the research team’s passion about the clinical implications of their findings and for their potential impact on primary care practice.

©galyna_p/Adobe Stock  Global Diabetes Prevalence Will Double by 2050, Affecting 1.3 Billion People: New Predictions
©galyna_p/Adobe Stock

"Without new and far-reaching approaches targeting not only risk factors but also the social and logistical barriers that limit access to treatment and medical attention, diabetes will continue to exert increasingly negative effects on the quality of life of individuals, health of populations, and the strength of global economies for decades to come."

© Fandorina Liza/Adobe stock
©Fandorina Lisa/Adobe Stock

“...it is undeniable that SGLT2 inhibitors reduce the risk of cardiovascular death in patients with cardio-renal-metabolic disease. In other words, these are agents with the potential to prevent or modify the course of cardiovascular disease, including cardiovascular mortality, in multiple patient populations.”

FDA Approves Low-Dose Colchicine as First Anti-inflammatory Therapy to Reduce Cardiovascular Events   FDA logo ©waldenmarus/stock.adobe.com.
©waldenmarus/Adobe Stock

“To treat coronary disease effectively, cardiologists must aggressively reduce inflammation and cholesterol. For appropriate patients already taking a statin, adding the anti-inflammatory drug colchicine at a dose of 0.5 mg daily has been proven to significantly lower risks of recurrent heart attack and stroke.”

©jarun011/Adobe Stock Testosterone Replacement Does Not Increase Risk for CV Events in Men with Hypogonadism, New Study Finds
©jarun011/Adobe Stock

“Because testosterone deficiency is not a life-threatening condition, uncertainty about cardiovascular outcomes has weighed on treatment decisions by clinicians and patients. Our findings may facilitate a more informed consideration of the potential benefits and risks of testosterone therapy among middle-aged and older men with hypogonadism.”

©Monkey Business/Adobe Stock  Healthy Lifestyle Linked to Primary CVD Prevention in Postmenopausal Women with Normal BMI
©Monkey Business/Adobe Stock

As the prevalence of overweight and obesity climb steadily worldwide, public health recommendations focus on lifestyle change targeting weight loss or weight maintenance in a “healthy” range. But these findings that suggest lifestyle modification to reduce CVD risk may be important even when BMI is normal. “Compared with those with the lowest level of HLI [healthy lifestyle index], even those with intermediate HLI scores, resulting from various levels of adherence to different lifestyle behaviors, have a lower CVD risk."

Related Videos
"Vaccination is More of a Marathon than a Sprint"
Vaccines are for Kids, Booster Fatigue, and Other Obstacles to Adult Immunization
Related Content
© 2024 MJH Life Sciences

All rights reserved.